Cerebrolysin is a peptide-based drug that is used in research for its potential neuroprotective and cognitive-enhancing effects. The drug is made up of a mixture of low molecular weight peptides and amino acids that are derived from porcine brain tissue. Cerebrolysin is typically available in a 215mg/ml solution and is packaged in 10ml vials.
While Cerebrolysin has shown promise in preclinical studies, it is important to note that it is not currently approved by regulatory agencies such as the FDA for clinical use in humans. The drug is intended for research purposes only and should only be used by qualified researchers who are conducting studies on the drug’s safety and efficacy.
Despite the lack of regulatory approval for clinical use, Cerebrolysin continues to be studied for its potential therapeutic benefits in a range of neurological conditions. Researchers are exploring the drug’s potential use in treating conditions such as Alzheimer’s disease, Parkinson’s disease, and stroke, among others.